Search results
Results from the WOW.Com Content Network
The second-generation Chevrolet Camaro is an American pony car produced by Chevrolet from 1970 through the 1981 model years. It was introduced in the spring of 1970. [1] Build information for model 123-12487 [2] was released to the assembly plants in February of that same year. It was longer, lower, and wider than the first generation Camaro.
The first-generation Chevrolet Camaro is an American pony car introduced by Chevrolet in the fall of 1966 for the 1967 model year. It used a brand-new rear-wheel-drive GM F-body platform and was available as a 2-door, 2+2 seat, hardtop, and convertible. The F-body was shared with the Pontiac Firebird for all generations.
1970 second generation Camaro. Introduced on February 26, 1970, the second-generation Camaro was produced through the 1981 model year, with cosmetic changes made for the 1974 and 1978 model years. The car was heavily restyled and became larger and wider with the new styling. Based on the F-body platform, the new Camaro was similar to its ...
The second-generation Camaro rolled into showrooms for the 1970 model year as a sleek fastback, but GM engineers had planned a station wagon model, too. ... The first was "Camaro" by The Cyrkle, a ...
Second-generation sulfonylureas have increased potency by weight, compared to first-generation sulfonylureas. [21] Similarly, ACCORD (Action to Control Cardiovascular Risk in Diabetes) [ 22 ] and the VADT (Veterans Affairs Diabetes Trial) [ 23 ] studies showed no reduction in heart attack or death in patients assigned to tight glucose control ...
Chevrolet Camaro (first generation) Chevrolet Camaro (second generation) Chevrolet Camaro (third generation) Chevrolet Camaro (fourth generation) Chevrolet Camaro (fifth generation) Chevrolet Camaro (sixth generation)
Carbutamide (brand name Glucidoral) is an anti-diabetic drug of the sulfonylurea class, developed by Servier. It is classified as first-generation. [1] It was patented in 1953 and approved for medical use in 1956. [2]
It is classified as a second-generation sulfonylurea. [4] Glimepiride was patented in 1979 and approved for medical use in 1995. [5] It is available as a generic medication. [2] In 2022, it was the 64th most commonly prescribed medication in the United States, with more than 10 million prescriptions. [6] [7]